Linked Life Data

6259398

Source:http://linkedlifedata.com/resource/pubmed/id/6259398

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1981-5-26
pubmed:abstractText
Of 117 patients in remission for at least 12 months after chemotherapy for confirmed Burkitt's lymphoma, 14 subsequently relapsed. Frequency of ever relapsing in this group varied from 12% 2 years after chemotherapy to 3-8% 3-6 years after chemotherapy. Risk of very late relapse (VLR) increased with the occurrence of meningeal disease and/or relapse before a remission of 12 months or more was achieved. The use of combination chemotherapy and especially prophylactic intrathecal methotrexate significantly lowered the risk of VLR (P less than 0.03). Serial testing for antibodies to Epstein-Barr viral capsid antigen to the diffuse and restricted components of the early antigen complex and to the Epstein-Barr virus-specific nuclear antigen revealed minor fluctuations but no consistent increases in antibody titers preceding detection of VLR. The serologic follow-up tests thus were not clinically useful for prediction of the imminence of a recurrence. Patients developing VLR generally maintained moderate-to-high titers of antibodies to restricted or diffuse components throughout the long remission periods, which indicated that they were not beyond the danger of a relapse at an unspecified time in the future.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0027-8874
pubmed:author
pubmed:issnType
Print
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
439-44
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
Very late relapses in patients with Burkitt's lymphoma: clinical and serologic studies.
pubmed:publicationType
Journal Article